Neil J. Littman, M.S. is the Founder and Managing Director at Bioverge, a venture capital firm exclusively dedicated to investing in early-stage, cutting-edge healthcare companies. Neil is primary interested in precision-medicine companies at the intersection of biology and technology that are utilizing advances in technology to modernize healthcare, from bench-to- bedside.

Previously, Neil was Vice President of Business Development at Notable Labs, an oncology focused startup and Bioverge portfolio company, where he leads the development of global corporate partnerships and contributed to the strategic vision of Notable as part of the Senior Leadership Team. Neil oversaw business development at Notable through the successful completion of the company’s $40 million Series B and was instrumental in negotiating multiple terms sheets to in-license clinical stage oncology assets.

Previously, Neil was a member of the Executive Leadership Team and Director of Business Development at the California Institute for Regenerative Medicine (CIRM). As part of CIRM’s leadership team, Neil helped develop the five-year strategic plan for managing and deploying CIRM’s $3 billion across the organization’s discovery, translational, and clinical stage stem cell and regenerative medicines programs. Neil was responsible for establishing collaborations with industry partners and investors to accelerate the development of CIRM-funded

programs. During his time at CIRM, Neil was responsible for managing the Therapeutics Group and oversaw a team of Ph.D. scientists responsible for >40 clinical stage therapies totaling over $500 million worth of CIRM investment. Prior to managing the Therapeutics Group, Neil oversaw the Strategic Infrastructure Group and was for managing over $125 million worth of supporting infrastructure programs, including: $30 million Stem Cell Center (partnership with IQVIA); $24 million Alpha Stem Cell Clinical Network (partnership with UCLA, UCSD, City of Hope, UC Irvine); $32 million iPSC Bank (partnership with Fujifilm); $40 million Genomics Center of Excellence (partnership with Stanford).

Prior to CIRM, Neil was a healthcare investment banker at Thomas Weisel Partners and Deutsche Bank and worked on transactions totaling over $1 billion. His primary focus was on strategic advisory and public and private financings.

Neil received a Master of Science in Biotechnology from The Johns Hopkins University, and a Bachelor of Arts in Molecular, Cellular and Development Biology from the University of Colorado, Boulder.